Albireo to Present at the 2021 Wedbush PacGrow Virtual Healthcare Conference
03 August 2021 - 2:30PM
Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company
developing novel bile acid modulators, today announced
that Ron Cooper, President and Chief Executive Officer and
Simon Harford, Chief Financial Officer, will present at the 2021
Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August
10, at 3:30 p.m. ET.
The live webcast of the presentation will be accessible from the
Media & Investors page of Albireo’s website,
ir.albireopharma.com. To ensure a timely connection to the webcast,
it is recommended that users register at least 15 minutes prior to
the scheduled start time. An archived version of the webcasts will
be available for replay in the Events & Presentations section
of the Media & Investors page of Albireo’s website for 30 days
following the event.
About AlbireoAlbireo Pharma is a rare liver
disease company focused on the development of novel bile acid
modulators to treat rare pediatric and adult liver diseases.
Albireo’s product, Bylvay, was approved by the U.S. FDA as the
first for the treatment of pruritus in patients with all sub-types
of progressive familial intrahepatic cholestasis (PFIC), and is
also being developed to treat other rare pediatric cholestatic
liver diseases with Phase 3 trials in Alagille syndrome and biliary
atresia, as well as an Open-label Extension (OLE) study for PFIC.
In Europe, Bylvay has been approved for the treatment of PFIC and
has been submitted for pricing and reimbursement approval. The
Company has also initiated a Phase 1 clinical trial for A3907 to
advance development in adult cholestatic liver disease, with
IND-enabling studies moving ahead with A2342 for viral and
cholestatic liver disease. Albireo was spun out from AstraZeneca in
2008 and is headquartered in Boston, Massachusetts, with its key
operating subsidiary in Gothenburg, Sweden. The Boston Business
Journal named Albireo one of the 2020 Best Places to Work in
Massachusetts for the second consecutive year. For more information
on Albireo, please visit www.albireopharma.com.
Media Contact:Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.comLisa Rivero,
617-947-0899, lisa.rivero@syneoshealth.com
Investor Contact:Hans Vitzthum, LifeSci
Advisors, LLC., 617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Apr 2023 bis Apr 2024